The Week in Review: September 15 – September 22, 2017

Friday, September 22, 2017 News Recap: Access to Treatment: This was a good week in terms of treatment access (but not, unfortunately, in terms of weather or seismic activity: How very, very sad).  Imagine being sick or on treatment in one of these stricken areas! In Canada Epclusa was approved for use in persons co-infected with HIV. This is very good news. Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpat...

Gilead Receives Approval in Canada for Expanded Indication of EPCLUSA® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

– New Data for First Approved Pan-genotypic Once-Daily Single Tablet Regimen for  Chronic Hepatitis C Virus Infection – MISSISSAUGA, ON, Sept. 21, 2017 /CNW/ - Gilead Sciences Canada, Inc. (Gilead Canada) today announced that Health Canada has granted a Notice of Compliance (NOC) for updated labeling of EPCLUSA® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults w...

The Week in Review: July 28 – August 4, 2017

Friday, August 4, 2017 Treatment: This last week saw the approval in the U.S. of AbbVie’s Mavyret, a pangenotypic also indicated as recuperation therapy for those with GT1 who have failed treatment with DAAs. U.S.: FDA approves Mavyret for Hepatitis C As well, the FDA has approved updated labeling for Epclusa to include use in patients co-infected with HIV. U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatmen...

U.S. FDA Approves Expanded Labeling for Epclusa® (Sofosbuvir/Velpatasvir) for the Treatment of Chronic Hepatitis C in Patients Co-Infected with HIV

FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (NASDAQ: GILD) today announced that the U.S. Food and Drug Administration (FDA) has approved updated labeling for Epclusa® (sofosbuvir 400mg/velpatasvir 100mg), the first all-oral, pan-genotypic, once-daily single tablet regimen (STR) for the treatment of adults with chronic hepatitis C virus (HCV) infection, to include use in patients co-infected with HIV. “HCV co-infection remains a major cause

Are people with HIV and HCV co-infection who are cured of hepatitis C with DAAs at increased risk for liver cancer?

People with HIV and hepatitis C virus (HCV) co-infection who are successfully treated for hepatitis C using interferon-free direct-acting antiviral (DAA) therapy do not appear to have an increased likelihood of developing hepatocellular carcinoma (HCC), according to a study presented at the Conference on Retroviruses and Opportunistic Infections (CROI 2017) this month in Seattle. More HCC cases are being diagnosed among people with co-infection cured of h

The Week in Review: Feb 3, 2017 – Feb 10, 2017

Friday, February 10, 2017 News Recap Liver Cancer In the news this week was a story about why Toronto, Canada, is a liver cancer hotspot. More than a thousand deaths from liver cancer every year in Ontario — and most of these occur in the Greater Toronto Area. The reasons: Hepatitis B & C in the immigrant populations, and the lack of screening of Baby Boomers in Canada.  This is terrible, especially considering that the survival rate from liver ...

Curing hepatitis C reduces the risk of diabetes & kidney failure in HIV/HCV-coinfected people

Curing hepatitis C infection substantially reduces the risk of developing type II diabetes in people with HIV/HCV coinfection, but does not reduce the risk of cardiovascular disease, cancers or other non-AIDS events, a study of coinfected patients treated in Spain between 2000 and 2008 has shown. The findings are published online ahead of print in the journal Hepatology. The study also found a trend towards a reduced risk of kidney failure in those cured

Hepatitis C and HIV medications can be adversely interacted when used together, URI pharmacy professor reports

A University of Rhode Island pharmacy professor and a graduate student have discovered potential complications in [sofosbuvir-containing regimens]. The Hepatitis C drug sofosbuvir can adversely interact with HIV drug tenofovir disoproxil [Viread], reports Bingfang Yan, professor of biomedical and pharmaceutical sciences in the College of Pharmacy/Academic Health Collaborative. Tenofovir disoproxil is listed as an essential medicine by the World Health Org

Tobacco Smoking Is Not Associated With Accelerated Liver Disease in Human Immunodeficiency Virus-Hepatitis C Coinfection: A Longitudinal Cohort Analysis.

Tobacco exposure does not appear to be associated with accelerated progression of liver disease in this prospective study of HIV-HCV coinfected individuals. Well surprise surprise!  Although tobacco smoking has been shown to be an independent risk factor for liver fibrosis in hepatitis C virus (HCV) infection in some cross-sectional studies, no longitudinal study has confirmed this relationship, and the effect of tobacco exposure on liver fibrosis in huma

HIV not a risk factor for fibrosis progression in people with hepatitis C

HIV co-infection is not associated with accelerated progression of liver fibrosis in people with hepatitis C virus (HCV) infection, according to US research published in the online edition of the Journal of Infectious Diseases. Factors linked with fibrosis progression were low fibrosis stage at baseline and flares in alanine aminotransferase (ALT) levels. The major strengths of the study were its large sample size and the fact that participants had at lea